Stocks Health care LFCR
NASDAQ · Health careLifecore Biomedical, Inc. DE (LFCR)
Lifecore Biomedical, Inc. DE reported revenue of $128.9M in fiscal 2025, up 0.5% from a year earlier. It posted a net loss of $38.7M. In fiscal 2025 capital spending exceeded operating cash flow by $13.6M. At September 30, 2026 it held $23M in cash against $161M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 4, 2026.
Key facts about Lifecore Biomedical, Inc. DE
- Net worth
- Lifecore Biomedical, Inc. DE has a market value (market cap) of $241.1M at the latest share price, and shareholders' equity of -$73.4M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $128.9M (+0.5% year on year), with a net loss of $38.7M.
- Cash flow
- In fiscal 2025 operations used $206K of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 4, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Lifecore Biomedical, Inc. DE's next report is expected around March 15, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Lifecore Biomedical, Inc. DE does
Lifecore Biomedical, Inc. DE is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker LFCR.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $128.9M | -$38.7M | -$1.27 | -$13.6M |
| 2024 | $128.3M | $12M | $0.33 | -$18.1M |
| 2023 | $103.3M | -$99.6M | -$3.32 | n/a |
| 2022 | $111.3M | -$116.7M | -$3.97 | -$48.8M |
| 2021 | $100.9M | -$32.3M | -$1.10 | -$2.8M |
| 2020 | $160.1M | -$38.2M | -$1.31 | -$29.3M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where LFCR ranks in Health care
Latest SEC filings
What Lifecore Biomedical, Inc. DE has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 5, 2026Additional proxy material DEFA14A
- November 5, 2026Other event 8-K
- November 4, 2026Quarterly report 10-Q · period to September 30, 2026Revenue fell 19% to $25.3M versus the same quarter last year; diluted EPS -$1.08 versus -$0.29.
- November 4, 2026
- October 30, 2026Form PREM14A filing PREM14A
- October 20, 2026Other event 8-K
- September 29, 2026Activist stake changed SCHEDULE 13D/A
- September 29, 2026Material agreement8-KLifecore Biomedical extended its contract manufacturing agreement with Alcon through 2034.
- September 28, 2026Activist stake changed SCHEDULE 13D/A
- September 28, 2026Additional proxy material DEFA14A
Insider trades
What the people running Lifecore Biomedical, Inc. DE did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| June 4, 2026 | Kiper Christopher SDirector, 10% owner | Received as pay | 25,907 | - |
| June 4, 2026 | Obus NelsonDirector | Received as pay | 25,907 | - |
| June 4, 2026 | Houde Lovas KatrinaDirector | Received as pay | 25,907 | - |
| June 4, 2026 | Schechter JoshuaDirector | Received as pay | 25,907 | - |
| June 4, 2026 | Aryeh JasonDirector | Received as pay | 25,907 | - |
| June 4, 2026 | Korenberg Matthew EDirector | Received as pay | 25,907 | - |
| June 4, 2026 | Antunes Humberto CalheirosDirector | Received as pay | 25,907 | - |
| June 4, 2026 | Johnson Paul HaroldDirector | Received as pay | 25,907 | - |
Who owns LFCR
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Legion Partners Holdings, LLC13D, may seek influence with 6 related filers | 17.3% | September 28, 2026 |
| Nelson Obus13D, may seek influence with 7 related filers | 14.3% | September 29, 2026 |
| Greenhaven Road Investment Management, L.P.13G, passive with 4 related filers | 9.8% | February 14, 2025 |
| 22NW Fund, LP13D, may seek influence with 6 related filers | 6.74% | July 2, 2026 |
Largest institutional holders
Insiders
10 insiders reported holding 1,658,097 shares in total, about $10.6M at the last price.
| Holder | Shares |
|---|---|
| Josephs PaulChief Executive Officer, Director | 592,915 |
| Salus Thomas D.Chief Legal & Administration | 246,333 |
| Obus NelsonDirector | 164,100 |
| Houde Lovas KatrinaDirector | 135,319 |
| Schechter JoshuaDirector | 133,080 |
| Kiper Christopher SDirector, 10% owner | 103,482 |
| Antunes Humberto CalheirosDirector | 72,967 |
| Aryeh JasonDirector | 69,967 |
| Johnson Paul HaroldDirector | 69,967 |
| Korenberg Matthew EDirector | 69,967 |
Questions about LFCR
What does Lifecore Biomedical, Inc. DE do?
Lifecore Biomedical, Inc. DE is a company in the Health care sector, listed on NASDAQ as LFCR. Its shares trade on NASDAQ under the ticker LFCR.
What is Lifecore Biomedical, Inc. DE's net worth?
Lifecore Biomedical, Inc. DE has a market value (market cap) of $241.1M at the latest share price, and shareholders' equity of -$73.4M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Lifecore Biomedical, Inc. DE profitable?
No. In fiscal 2025 it reported a net loss of $38.7M on revenue of $128.9M.
How much revenue does Lifecore Biomedical, Inc. DE make?
In fiscal 2025 Lifecore Biomedical, Inc. DE reported revenue of $128.9M. That is 0.5% more than a year earlier.
When did Lifecore Biomedical, Inc. DE last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 4, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the additional proxy material from November 5, 2026.
When is Lifecore Biomedical, Inc. DE's next earnings report?
Lifecore Biomedical, Inc. DE's next report is expected around March 15, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare LFCR with
Follow LFCR
Get an email when Lifecore Biomedical, Inc. DE files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Lifecore Biomedical, Inc. DE tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.